ENFIERA 100MG

Description
Enfiera is an anticancer medicine which prevents the growth and spread of cancer cells in the body. Enfiera also indicated for the treatment of Non- Hodgkins lymphoma or chronic lymphocytic and with combination with another anticancer drug like methotrexate is used for rheumatoid arthritis symptoms in adult treatment. 

Prescribed For
Enfiera 100mg and hyaluronidase human injection are given alone or combined with another drug to treat certain types of non-Hodgkin's lymphoma and chronic lymphocytic leukemia (cancer start in WBC). Enfiera 100mg injection is also used with methotrexate (Otrexup, Rasuvo, Xatmep, others) for the treatment rheumatoid arthritis symptoms in adults that have been already treated with some type of regimen known as tumor necrosis factor (TNF) inhibitor.

Mechanism of action
Enfiera 100mg is a type of class called monoclonal antibody and which is a new type of "targeted" cancer treatment and an integral part of the body's immune system. Naturally, the body builds antibodies in along with to an antigen which has entered the body and attach to the antigen for destruction by the immune system. An essential cells only aimed by monoclonal antibiotics, they may lead to less toxicity to healthy cell and it is usually treatment recommended only for cancers in which antigens (and the respective antibodies) have been already identified. 

Dosage & Administration
Enfiera 100mg is recommended to administer only through intravenous infusion not by IV push or bolus. 

PREMEDICATE BEFORE EACH INFUSION First infusion: 
initially, rate of 50 mg/hr is given, in not showing infusion toxicity, rate raised upto 50 mg/hr increments at intervals of 30 min and max of 400 mg/hr. Successive infusion: 100 mg/hr initiated rate, in not showing infusion toxicity, rate raised upto 100 mg/hr increments at intervals of 30 min and a max of 400 mg/hr. Premedication with corticosteroids must be considered if Enfiera 100mg combination with CHOP chemotherapy is not given.

Pregnancy
Category C: animal studies reproduction shown an adverse effect on the fetus. The drug has no sufficient and well-controlled studies in humans, using in pregnant women benefits by warrant use of the drug.

Lactation
Enfiera 100mg excreted into human milk is unknown. Due to the drug belongs to the large protein molecule, no information is available. Women should not breast-feed during Enfiera 100mg treatment and 12 months following the last dose.

Storage
Store at 2°C – 3°C Use the drug before expiry date Protected from direct sunlight Do not freeze or shake. Keep away from the children Discard the unused drug by asking the advice from a doctor or pharmacist.

FOR MORE INFORMATION:

EMAIL:
applepharmaceutical@gmail.com

PHONE:
+91- 9987711567

VISIT US:
anti-cancer-drugs.com/enfiera-100mg.php